$50.83
1.30% today
Nasdaq, Sep 24, 05:50 pm CET
ISIN
US10806X1028
Symbol
BBIO

BridgeBio Pharma Inc Stock price

$51.50
+4.21 8.90% 1M
+14.28 38.37% 6M
+24.06 87.68% YTD
+26.10 102.76% 1Y
+41.75 428.21% 3Y
+12.85 33.25% 5Y
+23.95 86.93% 10Y
+23.95 86.93% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-0.04 0.08%
ISIN
US10806X1028
Symbol
BBIO
Industry

Key metrics

Basic
Market capitalization
$9.8b
Enterprise Value
$11.8b
Net debt
$1.9b
Cash
$756.9m
Shares outstanding
191.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
41.8 | 20.5
EV/Sales
49.8 | 24.5
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-159.7%
Return on Equity
36.5%
ROCE
-71.4%
ROIC
-233.8%
Debt/Equity
-1.5
Financials (TTM | estimate)
Revenue
$235.8m | $479.2m
EBITDA
$-640.2m | $-402.2m
EBIT
$-645.7m | $-499.2m
Net Income
$-776.4m | $-655.8m
Free Cash Flow
$-667.5m
Growth (TTM | estimate)
Revenue
7.6% | 116.0%
EBITDA
-28.9% | 29.6%
EBIT
-28.4% | 13.5%
Net Income
-71.1% | -22.4%
Free Cash Flow
-59.0%
Margin (TTM | estimate)
Gross
96.2%
EBITDA
-271.5% | -83.9%
EBIT
-273.8%
Net
-329.3% | -136.8%
Free Cash Flow
-283.1%
More
EPS
$-4.1
FCF per Share
$-3.5
Short interest
17.5%
Employees
728
Rev per Employee
$300.0k
Show more

Is BridgeBio Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

BridgeBio Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a BridgeBio Pharma Inc forecast:

24x Buy
92%
2x Hold
8%

Analyst Opinions

26 Analysts have issued a BridgeBio Pharma Inc forecast:

Buy
92%
Hold
8%

Financial data from BridgeBio Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
236 236
8% 8%
100%
- Direct Costs 8.97 8.97
275% 275%
4%
227 227
5% 5%
96%
- Selling and Administrative Expenses 399 399
91% 91%
169%
- Research and Development Expense 473 473
7% 7%
201%
-640 -640
29% 29%
-272%
- Depreciation and Amortization 5.51 5.51
14% 14%
2%
EBIT (Operating Income) EBIT -646 -646
28% 28%
-274%
Net Profit -776 -776
71% 71%
-329%

In millions USD.

Don't miss a Thing! We will send you all news about BridgeBio Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BridgeBio Pharma Inc Stock News

Neutral
GlobeNewsWire
2 days ago
PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one late breaking clinical trials oral presentation, one oral presentation, and three poster sessions will be shared at the Heart Failure Society of America (HFSA) Annual Scientific M...
Neutral
GlobeNewsWire
14 days ago
PALO ALTO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that the compensation committee of its board of directors (the “committee”) approved equity grants in the form of restricted stock units (“RSUs”) to new employees under the Company's Amend...
Neutral
Seeking Alpha
14 days ago
BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call Company Participants Ananth Sridhar Conference Call Participants Rachel Gafni Scott Adler Tyler Van Buren - TD Cowen, Research Division Biren Amin - Piper Sandler & Co., Research Division Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Lin Tsai - Jefferies LLC, Research Divisio...
More BridgeBio Pharma Inc News

Company Profile

BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

Head office United States
CEO Neil Kumar
Employees 728
Founded 2015
Website bridgebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today